Ozagrel

Ozagrel

Details
Ozagrel can selectively inhibit thromboxane synthetase, thereby suppressing the production of thromboxane A2 and promoting the production of prostacyclin (PGI2), improving the balance between the two. Ultimately, it inhibits platelet aggregation, alleviates vascular spasm, and improves the microcirculation and energy metabolism disorders during local cerebral ischemia.
Category
Non Steroid
Share to
Send Inquiry
Description
Technical Parameters

Introduction

 

 

Ozagrel can selectively inhibit thromboxane synthetase, thereby suppressing the production of thromboxane A2 and promoting the production of prostacyclin (PGI2), improving the balance between the two. Ultimately, it inhibits platelet aggregation, alleviates vascular spasm, and improves the microcirculation and energy metabolism disorders during local cerebral ischemia.

 

Specifications

In house/CP

Chemical Name

(E)-3-(4 - (1 - H - imidazol - 1 - ylmethyl) phenyl) - 2 - propenoic acid

Molecular formula

C13H12N2O2

CAS NO.

82571-53-7

Packing

1kg/tin

INDICATION

Suitable for the treatment of acute thrombotic cerebral infarction and motion disorders associated with cerebral infarction.

Category

Anticoagulant drugs

Storage

Protect from light, seal the container, and store in a cool place.

Pharmacological Actions

 

Inhibition of Thromboxane Synthesis

Ozagrel selectively inhibits thromboxane synthetase. This enzyme is crucial in the biosynthesis of thromboxane A₂, a potent vasoconstrictor and platelet aggregator. By blocking this enzyme, ozagrel reduces the production of thromboxane A₂.

Promotion of Prostacyclin Production

Concurrently, ozagrel has a promoting effect on the production of prostacyclin (PGI₂). Prostacyclin is a vasodilator and inhibitor of platelet aggregation. It counterbalances the effects of thromboxane A₂. The promotion of PGI₂ production by ozagrel helps to restore the balance between these two opposing factors in the body.

Overall Effects

Through the dual actions of inhibiting thromboxane A₂ production and promoting prostacyclin production, ozagrel effectively inhibits platelet aggregation. This prevents the formation of blood clots, which are often involved in the pathogenesis of cerebrovascular diseases. Additionally, it alleviates vascular spasm, improving blood flow in the affected blood vessels. Consequently, it helps to improve the microcirculation and energy metabolism disorders in the local cerebral ischemia area, reducing the damage to brain tissue caused by ischemia.

Clinical Applications

 

Ischemic Stroke

It is mainly used for the treatment of acute ischemic stroke. By improving cerebral blood flow and preventing further platelet aggregation and thrombosis, ozagrel can help reduce the size of the ischemic lesion and improve the neurological function of patients. It is often administered intravenously in the early stage of stroke to achieve the best therapeutic effect.

Other Applications

In addition to ischemic stroke, ozagrel may also be used in some other conditions related to abnormal platelet aggregation and vascular spasm, such as transient ischemic attacks and some peripheral vascular diseases. However, its use in these areas may be less common and requires further clinical studies to confirm its efficacy and safety.

 

Hot Tags: ozagrel, China ozagrel manufacturers, suppliers, factory, Artemether 71963 77 4, Ozagrel, Ozagrel Sodium, Abiraterone Acetate, Artemisinin 63968 64 9, Propiverine Hydrochloride

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!